Journals / Namık Kemal Tıp Dergisi / 2020 / Cilt: 8 - Sayı: 3

COVİD - 19 from Rheumatology Perspective

ROMATOLOJİ PERSPEKTİFİNDEN COVID-19

Pages
557–563
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Also, we summarized the current data about the effectiveness of immunosuppressive drugs on COVID-19.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:World Health Organization declared coronavirus disease-19 (COVID-19) as pandemic since 11 March 2020.
📊
Key Findings & Data:Herein, new human coronavirus, SARS-CoV2 is the etiologic agent of the disease.
💡
Conclusion & Impact:Also, we summarized the current data about the effectiveness of immunosuppressive drugs on COVID-19.
🔬Design:Review & Systematic Survey
📍Scope:2020 Verileri
⚙️Variables:Domain Parameters

Abstract

World Health Organization declared coronavirus disease-19 (COVID-19) as pandemic since 11 March 2020. Herein, new human coronavirus, SARS-CoV2 is the etiologic agent of the disease. Also, it has been a global health problem since it was detected in Chinese province of Wuhan at December 2019. COVID-19 has several different clinical variations from mild disease to acute respiratory distress syndrome. For the treatment of the disease, several remedies have been administered. Even though, anecdotal data showed somewhat effectiveness of those drugs for the treatment of the disease, there has been no accurate scientific knowledge proofing these. Therefore, main purpose of this review was discussing how the physicians arrange the therapies of the rheumatologic diseases during COVID-19, especially while patients are under immunosuppressive drugs. Also, we summarized the current data about the effectiveness of immunosuppressive drugs on COVID-19.

Özet

Korona virüs hastalığı-19 (COVID-19), Dünya Sağlık Örgütü tarafından 11 Mart 2020'de pandemi olarak tanımlanmıştır. SARS-CoV-2, COVID-19'a neden olan ve yeni gelişen insan korona virüsüdür. Bu virüs, ilk olarak Aralık 2019'da Çin'in Wuhan şehrinde tespit edilmiştir. COVID-19, hafif hastalıktan, şiddetli solunum yetmezliğine kadar farklı klinik spektrumunda ortaya çıkabilir. Şu an COVID-19 hastalarının yönetiminde kesin bir fikir birliği yoktur. Bununla birlikte, diğer hastalıklar için önerilen bazı ilaçların, bu enfeksiyonun tedavisinde potansiyel olarak etkili olabileceği gösterilmiştir. Bu derlemenin amacı, COVID-19 pandemisinde romatizmal hastalıkları, savunma sistemi etkileyici ilaç kullanan hastaların yönetimini ve savunma sistemini baskılayıcı ilaçların COVID-19 tedavisinde kullanımı dahil olmak üzere romatoloji ile ilgili yönlerini gözden geçirmektir.

🔖

Cite This Article

TEZCAN, M. E., MERCAN, R. (2020). COVİD - 19 from Rheumatology Perspective. Namık Kemal Tıp Dergisi, Cilt: 8 - Sayı: 3, 557–563. https://ajindex.com/articles/288965

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of autoimmunity. 2020;109:102433
  2. Hu Y, Sun J, Dai Z, et al. Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis. Journal of clinical virology. 2020;127:104371
  3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62
  4. Sangha O. Epidemiology of rheumatic diseases. Rheumatology. 2000;39 (S2):3-12
  5. Atzeni F, Bendtzen K, Bobbio-Pallavicini F, et al. Infections and treatment of patients with rheumatic diseases. Clinical and experimental rheumatology. 2008; 26(1 Suppl 48):67-73
  6. EULAR COVID-19 Database. 18.05.2020 ed.
  7. Emmi G, Bettiol A, Mattioli I, et al. SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmunity reviews. 2020; 102575. doi:10.1016/j.autrev.2020.102575
  8. Favalli EG, Agape E, Caporali R. Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis. The Journal of rheumatology. 2020;
  9. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Annals of the rheumatic diseases. 2020; 79(5):667-8
  10. Favalli EG, Ingegnoli F, Cimaz R, Caporali R. What is the true incidence of COVID-19 in patients with rheumatic diseases? Annals of the rheumatic diseases. 2020; doi:10.1136/annrheumdis-2020-217615
  11. Cheng C, Li C, Zhao T, et al. COVID-19 with rheumatic diseases: a report of 5 cases. Clinical rheumatology. 2020;1‐5. doi:10.1007/s10067-020-05160-x
  12. Mathian A, Mahevas M, Rohmer J, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under longterm treatment with hydroxychloroquine. Annals of the rheumatic diseases. 2020;79(6):837‐39
  13. Bozzalla Cassione E, Zanframundo G, Biglia A, Codullo V, Montecucco C, Cavagna L. COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine. Annals of the rheumatic diseases. 2020; doi:10.1136/annrheumdis-2020-217717
  14. Dixon WG, Suissa S, Hudson M. The association between systemi